Loading organizations...
§ Private Profile · Auckland, Auckland, New Zealand
Medical device company developing Gastric Alimetry, non-invasive wearable devices and software to diagnose gastrointestinal disorders.
Based in Auckland, New Zealand, Alimetry develops non-invasive wearable medical devices and cloud-based diagnostic software to evaluate and monitor gastrointestinal disorders. The company's flagship system, Gastric Alimetry, utilizes skin-surface electrodes to map stomach electrical activity while a paired application tracks patient symptoms, replacing invasive procedures like endoscopies. Operating across hospitals in the United States, the United Kingdom, and New Zealand, the enterprise has completed over 30 clinical studies and secured its fourth FDA clearance alongside a CPT III reimbursement code. To finance its ongoing commercial expansion, Alimetry raised an oversubscribed US$18 million Series A2 funding round in October 2024, backed by venture capital firms including GD1 and Icehouse Ventures. The medical technology company was originally founded in 2019 as a research spin-out from the University of Auckland by co-founders Greg O’Grady and Armen Gharibans.
Alimetry has raised $18.0M across 1 funding round.
Alimetry has raised $18.0M in total across 1 funding round.
Alimetry has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Series A in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 24, 2024 | $18M Series A | GD1 | — | Announced |
Alimetry has raised $18.0M in total across 1 funding round.
Alimetry's investors include GD1.